Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease.

Kobeissy AA, Hashash JG, Jamali FR, Skoury AM, Haddad R, El-Samad S, Ladki R, Aswad R, Soweid AM.

World J Gastroenterol. 2012 May 21;18(19):2390-5. doi: 10.3748/wjg.v18.i19.2390.

3.

[A randomized, prospective, comparative, multicenter study of rabeprazole and ranitidine in the treatment of reflux esophagitis].

Jeong HY, Lee BS, Sung JK, Lee TY, Yoon SJ, Kim SJ, Chung IK, Lee SH, Shin JE, Lee DS, Baek JT, Nam SW, Yoon SJ, Kim SH, Lee GS, Lee JM, Kim AN, Oh JI.

Korean J Gastroenterol. 2006 Jan;47(1):15-21. Korean.

4.

Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study.

Suzuki T, Matsushima M, Masui A, Tsuda S, Imai J, Nakamura J, Tsukune Y, Uchida T, Yuhara H, Igarashi M, Koike J, Mine T.

World J Gastroenterol. 2015 Apr 28;21(16):5023-31. doi: 10.3748/wjg.v21.i16.5023.

6.

Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan.

Miwa H, Sasaki M, Furuta T, Koike T, Habu Y, Ito M, Fujiwara Y, Wada T, Nagahara A, Hongo M, Chiba T, Kinoshita Y; ACID-RELATED SYMPTOM (ARS) RESEARCH GROUP.

Aliment Pharmacol Ther. 2007 Jul 1;26(1):69-77.

7.

Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.

Richter JE, Campbell DR, Kahrilas PJ, Huang B, Fludas C.

Arch Intern Med. 2000 Jun 26;160(12):1803-9.

PMID:
10871974
8.

[Long-term impact on quality of life in patients with gastroesophageal reflux disease after 52-week rabeprazole treatment].

Yang XL, Liu XH, Ke MY, Song ZQ, Yuan YZ, Luo JY, Hou XH.

Zhonghua Yi Xue Za Zhi. 2009 Sep 15;89(34):2404-7. Chinese.

PMID:
20137694
9.

Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.

Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L; FAST Trial Investigators.

Aliment Pharmacol Ther. 2002 Mar;16(3):445-54. Erratum in: Aliment Pharmacol Ther 2002 May;16(5):1035.

10.

Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease.

Bytzer P, Blum A, De Herdt D, Dubois D; Trial Investigators.

Aliment Pharmacol Ther. 2004 Jul 15;20(2):181-8.

11.

Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies.

Howden CW, Henning JM, Huang B, Lukasik N, Freston JW.

Am J Gastroenterol. 2001 Jun;96(6):1704-10. Erratum in: Am J Gastroenterol 2001 Sep;96(9):2809.

PMID:
11419818
12.

Predicting the efficacy of proton pump inhibitors in patients with non-erosive reflux disease before therapy using dual-channel 24-h esophageal pH monitoring.

Shimatani T, Sugimoto M, Nishino M, Adachi K, Furuta K, Ito M, Kurosawa S, Manabe N, Mannen K, Hongo M, Chiba T, Kinoshita Y; Acid-Related Symptom Research (ARS) Group.

J Gastroenterol Hepatol. 2012 May;27(5):899-906. doi: 10.1111/j.1440-1746.2011.06975.x.

PMID:
22098590
13.

Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.

Hongo M, Miwa H, Kusano M; J-FAST group.

J Gastroenterol Hepatol. 2012 May;27(5):913-8. doi: 10.1111/j.1440-1746.2011.07042.x.

PMID:
22142515
14.

Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg.

Morgan DG, O'Mahony MF, O'Mahony WF, Roy J, Camacho F, Dinniwell J, Horbay GL, Husein-Bhabha FA; RAB-GRD-3002 Study Group.

Can J Gastroenterol. 2007 Dec;21(12):820-6.

15.

Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease.

Kinoshita Y, Ashida K, Hongo M; Japan Rabeprazole Study Group for NERD.

Aliment Pharmacol Ther. 2011 Jan;33(2):213-24. doi: 10.1111/j.1365-2036.2010.04508.x. Epub 2010 Nov 14.

16.

Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia.

Fock KM, Teo EK, Ang TL, Chua TS, Ng TM, Tan YL.

World J Gastroenterol. 2005 May 28;11(20):3091-8.

17.
18.

Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) study.

Rush DR, Stelmach WJ, Young TL, Kirchdoerfer LJ, Scott-Lennox J, Holverson HE, Sabesin SM, Nicholas TA.

J Fam Pract. 1995 Aug;41(2):126-36.

PMID:
7636452
19.

Observational comparative trial of the efficacy of proton pump inhibitors versus histamine-2 receptor antagonists for uninvestigated dyspepsia.

Nagahara A, Asaoka D, Hojo M, Oguro M, Shimada Y, Ishikawa D, Osada T, Kawabe M, Yoshizawa T, Otaka M, Watanabe S.

J Gastroenterol Hepatol. 2010 May;25 Suppl 1:S122-8. doi: 10.1111/j.1440-1746.2009.06218.x.

PMID:
20586853
20.

Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi-centers with 185 patients.

Komatsu-Tanaka M, Iwakiri R, Fujimoto K, Fujiwara Y, Inamori M, Tanaka J, Shimatani T, Akiyama J, Ando T, Manabe N, Kinjo F, Deguchi R, Kusano M.

Dig Endosc. 2012 Nov;24(6):407-11. doi: 10.1111/j.1443-1661.2012.01301.x. Epub 2012 Apr 8.

PMID:
23078431

Supplemental Content

Support Center